China partnerships lead biopharma deal surge in Q1 2026

April 23, 2026

China partnerships lead biopharma deal surge in Q1 2026

Biopharma deal value reached $79.22 billion in the first quarter (Q1) 2026, marking a strong start to the year and an increase of about 17% from $67.6 billion in Q1 2025 and similar to $78.93 billion in Q4 2025. The total is the highest first-quarter tally in recent years, and the highest quarter since Q4 2025 brought $80.65 billion.

Source: bioworld

Publication

The World Dispatch

Source: World News API

Keywords: bioworld, cidara therapeutics inc., abbvie inc., remegen co. ltd., deals and m&a, avidity biosciences inc., eli lilly and co., atrium therapeutics inc., novartis ag, innovent biologics inc., analysis and data insight, merck & co. inc., ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS